A Mount Sinai-led team of international investigators, in collaboration with Novartis, the University of Oxford, and other renowned scientists in the field, has gained new understanding on the role of relapses on long-term outcomes, the role of worsening that occurs independent of relapse activity, and the benefit of treatment on longer-term outcomes.